Adalank is marketed as a stabilized or modified analogue of Selank, a synthetic peptide originally investigated for anxiolytic and neuroactive effects. However, the public scientific record for Adalank itself is extremely limited, and claims about its properties are largely extrapolated from Selank rather than supported by dedicated Adalank studies.

Product Information

Unlike Selank, which has a defined peptide sequence and a published research record, Adalank does not currently have a clearly documented independent sequence, pharmacokinetic profile, or clinical-trial literature under that name. A 2026 database review reported no PubMed records specifically indexed under “Adalank.”

How It Works

A validated mechanism for Adalank has not been established. Proposed mechanisms are generally borrowed from Selank research, including potential effects on neurotrophic and neurotransmitter-related pathways, but these mechanisms should not be assumed to apply identically to an analogue whose structure has not been independently characterized.

POTENTIAL BENEFITS

1. Selank-Analogue Research

Adalank is primarily relevant to research examining whether structural modification of Selank can alter stability, duration, or biological activity. This is currently a proposed research rationale rather than a clinically demonstrated advantage.

2. Neurotrophic Research

Selank research has investigated neurotrophin-related signaling, including BDNF pathways. These findings provide background for Adalank research, but direct evidence for Adalank itself remains limited.

3. Cognitive Research

Modified Selank analogues are of interest in research into attention, memory, stress response, and cognitive signaling. However, these areas remain substantially better documented for Selank than for Adalank.

4. Peptide-Stability Research

The primary claimed distinction of Adalank is improved stability compared with Selank. Because independent stability studies are not publicly established, this remains an important area for future characterization.

Dosage

There is no established human dosage for Adalank. Some commercial sources publish microgram-level protocols, but these are vendor claims rather than validated clinical dosing data. The absence of dedicated human trials means Selank dosing should not simply be transferred to Adalank.

Side Effects

A reliable human safety profile has not been established for Adalank. The lack of dedicated clinical studies means its tolerability, pharmacokinetics, metabolism, and long-term effects remain uncertain.

References

1. Adalank — literature and PubMed evidence review
2. Adalank commercial research profile and claimed protocols
3. Selank research — PubMed
4. Selank and neurotrophic-factor research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The combination is designed to influence complementary pathways involved in appetite, glucose regulation, and body-weight control.

Product Information

Cagrilintide acts on amylin receptors, while semaglutide activates GLP-1 receptors. Clinical development has evaluated the two compounds as a once-weekly fixed-dose combination, including phase 3 studies in obesity and type 2 diabetes.

How It Works

Semaglutide activates GLP-1 receptors involved in appetite and glucose regulation, while cagrilintide mimics amylin signaling involved in satiety and post-meal metabolic control. Their complementary mechanisms are intended to produce combined effects on energy intake and glucose metabolism.

POTENTIAL BENEFITS

1. Weight-Management Research

Phase 3 clinical research has demonstrated substantial body-weight reductions with once-weekly CagriSema. In REIMAGINE 1, the 2.4 mg + 2.4 mg combination produced a mean relative body-weight reduction of 13.8% at week 40 in adults with early-stage type 2 diabetes.

2. Glycemic-Control Research

CagriSema has been evaluated in people with type 2 diabetes, including participants receiving basal insulin. Recent phase 3 research demonstrated improved HbA1c compared with placebo and relevant comparator groups.

3. Appetite & Satiety Research

GLP-1 and amylin signaling both influence food intake and satiety. Combining these pathways provides a research model for studying multiple physiological signals controlling energy consumption.

4. Dual-Pathway Metabolic Research

CagriSema is particularly relevant to research examining whether complementary incretin and amylin signaling can produce broader metabolic effects than either pathway alone.

Dosage

Clinical trials have evaluated CagriSema using 1.0 mg + 1.0 mg and 2.4 mg + 2.4 mg weekly target doses, with dose escalation used during treatment. These are investigational trial regimens and should not be treated as an established general-use dosing protocol.

Side Effects

Gastrointestinal adverse events are among the most frequently reported effects in clinical studies. Recent phase 3 research reported nausea and other gastrointestinal disorders among the most common adverse events, consistent with the pharmacology of GLP-1 receptor agonism and previous cagrilintide data.

References

1. REIMAGINE 2 — Cagrilintide-semaglutide phase 3 trial, PubMed
2. REIMAGINE 3 — Cagrilintide-semaglutide phase 3 trial, PubMed
3. REIMAGINE 1 — Cagrilintide-semaglutide phase 3a trial, PubMed
4. CagriSema cardiovascular outcomes study — ClinicalTrials.gov
5. Cagrilintide and amylin-receptor research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Tirzepatide is a long-acting GIP and GLP-1 receptor agonist developed for metabolic disease. It has extensive clinical evidence in type 2 diabetes and obesity and is marketed in the United States as Mounjaro and Zepbound for different indications.

Product Information

Tirzepatide is a modified peptide engineered for prolonged activity after once-weekly administration. Its dual incretin mechanism combines GIP receptor activation with GLP-1 receptor activation, affecting insulin secretion, glucagon regulation, appetite, and energy balance.

How It Works

Tirzepatide activates both GIP and GLP-1 receptors. These pathways enhance glucose-dependent insulin secretion and influence appetite and energy intake, while the combined signaling produces broad metabolic effects.

POTENTIAL BENEFITS

1. Blood-Glucose Research

Tirzepatide produces substantial reductions in HbA1c in clinical trials involving type 2 diabetes. Its dual incretin activity contributes to improved glucose regulation.

2. Weight-Management Research

Large clinical studies have demonstrated significant body-weight reductions in adults with obesity or overweight. This has made tirzepatide a major subject of modern metabolic research.

3. Insulin-Sensitivity Research

GIP and GLP-1 signaling influence insulin secretion and metabolic regulation. Tirzepatide has therefore been investigated extensively for changes in insulin sensitivity and broader cardiometabolic markers.

4. Metabolic-Disease Research

Tirzepatide research extends beyond glucose and body weight into cardiovascular risk factors, fatty liver disease, sleep apnea, and other obesity-associated conditions.

Dosage

For Zepbound, the current U.S. prescribing information starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Further increases can be made in 2.5 mg increments at intervals of at least 4 weeks, with maintenance doses of 5, 10, or 15 mg once weekly depending on indication and tolerability.

Side Effects

The most common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Important warnings include pancreatitis, gallbladder disease, acute kidney injury associated with severe gastrointestinal reactions, and the boxed warning concerning thyroid C-cell tumors observed in rodents.

References

1. FDA — current Zepbound (tirzepatide) prescribing information
2. Tirzepatide and type 2 diabetes — SURPASS clinical research.
3. Tirzepatide and obesity — SURMOUNT clinical research.
4. Tirzepatide cardiovascular and metabolic research.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Semaglutide is a long-acting GLP-1 receptor agonist with extensive clinical evidence in type 2 diabetes, obesity, cardiovascular risk reduction, and related metabolic conditions.

Product Information

Semaglutide is structurally related to human GLP-1 and has approximately 94% sequence homology with human GLP-1. It activates GLP-1 receptors involved in glucose-dependent insulin secretion, appetite regulation, gastric emptying, and energy balance.

How It Works

Semaglutide activates GLP-1 receptors in the pancreas, brain, gastrointestinal tract, and other tissues. It increases glucose-dependent insulin secretion, reduces glucagon secretion when glucose is elevated, slows gastric emptying, and influences appetite-regulating pathways.

POTENTIAL BENEFITS

1. Blood-Glucose Research

Semaglutide has demonstrated clinically meaningful reductions in blood glucose and HbA1c in people with type 2 diabetes. Its glucose-dependent mechanism helps explain its established role in diabetes treatment.

2. Weight-Management Research

Large clinical trials have demonstrated substantial body-weight reductions with once-weekly semaglutide alongside lifestyle intervention. The compound is therefore extensively studied in obesity and metabolic research.

3. Cardiovascular Research

Semaglutide has been studied in cardiovascular-risk populations, with clinical evidence supporting cardiovascular risk reduction in specified patient groups. Current U.S. labeling includes cardiovascular-risk indications for selected populations.

4. Metabolic Research

Beyond weight and glucose, semaglutide has been investigated in areas including cardiovascular disease, kidney outcomes, and metabolic liver disease. Its broad research profile reflects the wide physiological distribution of GLP-1 signaling.

Dosage

For the current U.S. injectable Wegovy formulation, treatment is initiated at 0.25 mg once weekly for 4 weeks, followed by gradual escalation. The labeled maintenance dosage for most weight-management indications is 2.4 mg once weekly, with 1.7 mg available as an alternative maintenance dose in appropriate circumstances.

Side Effects

The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Important labeled warnings include acute pancreatitis, gallbladder disease, and the contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2.

References

1. FDA — current Wegovy (semaglutide) prescribing information
2. FDA — semaglutide formulation and mechanism information
3. Semaglutide and cardiovascular outcomes — PubMed
4. Semaglutide and obesity clinical trial — PubMed
5. Semaglutide in type 2 diabetes — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Trevogrumab is a monoclonal antibody designed to inhibit myostatin (GDF-8). It has been investigated as a strategy for preserving skeletal muscle during weight loss and for modifying muscle-related outcomes.

Product Information

Trevogrumab is an investigational anti-myostatin antibody developed by Regeneron. By binding myostatin, it is intended to reduce signaling that normally restrains skeletal muscle growth. Clinical development has increasingly examined its use alongside obesity therapies.

How It Works

Trevogrumab binds myostatin and prevents it from activating its normal signaling pathway. Because myostatin acts as a negative regulator of skeletal muscle growth, blocking the pathway can alter muscle mass and composition.

POTENTIAL BENEFITS

1. Myostatin Research

Trevogrumab provides a targeted way to investigate the biological role of myostatin in humans. Blocking GDF-8 signaling allows researchers to study how this pathway influences muscle maintenance.

2. Muscle-Preservation Research

Recent clinical development has focused on whether myostatin inhibition can preserve lean mass during substantial weight loss. A 2026 clinical report evaluated trevogrumab alongside semaglutide in adults with obesity.

3. Body-Composition Research

The compound is relevant to research distinguishing total weight reduction from changes in lean and fat mass. This is particularly important in metabolic research where body composition is an important endpoint.

4. Muscle-Regeneration Research

Myostatin signaling is closely involved in skeletal-muscle growth and remodeling. Trevogrumab therefore provides a research tool for examining whether targeted inhibition can modify muscle physiology.

Dosage

Trevogrumab remains investigational, so there is no established clinical dosage for general use. Recent clinical research has evaluated doses including 75 mg, while other trial programs have investigated different dose levels and schedules. These remain study-specific exposures rather than an established treatment regimen.

Side Effects

The safety profile remains under clinical investigation. As an antibody targeting a major muscle-growth pathway, potential effects must be evaluated through controlled trials rather than inferred solely from preclinical myostatin research.

References

1. Recent trevogrumab/semaglutide clinical-trial report
2. Trevogrumab and myostatin inhibition — PubMed
3. Myostatin inhibition and skeletal-muscle biology — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Tesamorelin + Ipamorelin combines tesamorelin, a GHRH analogue, with ipamorelin, a selective growth hormone secretagogue. The combination is designed around two complementary mechanisms for stimulating growth hormone secretion.

Product Information

Tesamorelin has established clinical research involving GH and IGF-1 signaling, while Ipamorelin has been investigated as a selective GH secretagogue. However, there is currently no published controlled trial specifically evaluating the tesamorelin + ipamorelin combination. Evidence from each compound should therefore remain separate.

How It Works

Tesamorelin activates the GHRH pathway, while Ipamorelin activates the growth hormone secretagogue receptor. Both pathways influence pituitary GH secretion, providing the rationale for studying their combined effects.

POTENTIAL BENEFITS

1. Growth Hormone Research

Tesamorelin has demonstrated significant effects on GH and IGF-1 signaling in clinical research. Ipamorelin adds a distinct secretagogue pathway, making the combination relevant to GH-axis investigations.

2. IGF-1 Research

Tesamorelin increases circulating IGF-1 through stimulation of endogenous GH secretion. This provides a well-characterized downstream marker for research involving the GH axis.

3. Body-Composition Research

Tesamorelin has been clinically studied in relation to visceral adipose tissue and body composition. The combination with Ipamorelin is marketed around similar GH-axis research, although the combined formulation itself has not been clinically evaluated.

4. Endocrine Signaling Research

Using a GHRH analogue together with a GH secretagogue provides a model for studying how separate stimulatory signals converge on pituitary GH secretion.

Dosage

There is no established dosage for the Tesamorelin + Ipamorelin combination. Tesamorelin has been clinically studied at 2 mg once daily in its approved formulation, while Ipamorelin has separate experimental dosing data. These should not be combined into a self-directed dosing protocol.

Side Effects

GH-axis stimulation can produce headache, injection-site reactions, fluid retention, joint discomfort, and changes in glucose metabolism. Tesamorelin can also increase IGF-1, requiring monitoring in clinical use.

References

1. Review of Tesamorelin + Ipamorelin research evidence
2. Tesamorelin effects on visceral adipose tissue — PubMed
3. Tesamorelin and GH/IGF-1 signaling — PubMed
4. Ipamorelin clinical research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

CJC-1295 (No DAC) + GHRP-6 combines a GHRH-related peptide with a growth hormone secretagogue. The combination is designed around complementary pathways involved in stimulating growth hormone release.

Product Information

CJC-1295 No DAC is generally described as a shorter-acting GHRH analogue, while GHRP-6 activates the growth hormone secretagogue receptor. Human studies have demonstrated that GHRP-6 can strongly stimulate GH release and that GHRP-6 and GHRH can produce synergistic GH responses. However, clinical evidence for this exact CJC-1295 No DAC combination is limited.

How It Works

CJC-1295 No DAC is intended to stimulate the GHRH pathway, while GHRP-6 activates the growth hormone secretagogue receptor. These pathways can converge at the pituitary to increase GH secretion.

POTENTIAL BENEFITS

1. Growth Hormone Research

GHRP-6 has demonstrated strong GH-secretagogue activity in human research. This makes the combination relevant to experiments examining controlled stimulation of the GH axis.

2. GHRH & Secretagogue Interaction

Human studies have shown that GHRH and GHRP-6 can produce a synergistic increase in GH secretion. This provides the biological rationale for studying complementary stimulation of the two pathways.

3. IGF-1 Research

Growth hormone is an important upstream regulator of IGF-1 production. Research involving GH secretagogues therefore provides a useful model for studying downstream GH/IGF-1 signaling.

4. Pituitary-Endocrine Research

The combination allows researchers to examine interactions between GHRH signaling and secretagogue-receptor activation. This can help characterize how different GH-stimulating pathways influence pituitary responses.

Dosage

There is no established clinical dosage for CJC-1295 No DAC + GHRP-6. Human studies of GHRP-6 have used protocols including 1 microgram/kg intravenously, while clinical CJC-1295 studies have involved different formulations and doses. These component-specific protocols should not be treated as a validated dose for the combination.

Side Effects

Potential concerns include headache, flushing, appetite changes, fluid retention, and alterations in glucose or other endocrine pathways. The long-term safety profile of the exact combination remains insufficiently characterized.

References

1. GHRP-6 requires endogenous GHRH for maximal GH stimulation — PubMed
2. GHRP-6 and GHRH effects on GH secretion — PubMed
3. GHRP-6 + GHRH synergistic GH response — PubMed
4. CJC-1295 human pharmacology — PubMed
5. CJC-1295 and GH pulsatility — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

REM Blend is a sleep-oriented research formulation combining DSIP, Pinealon, melatonin, and GABA. The combination brings together peptide and non-peptide ingredients investigated in sleep, circadian, neurological, and relaxation research.

Product Information

Current research-market listings describe a REM Blend containing approximately DSIP 10 mg + Pinealon 10 mg + melatonin 50 mg + GABA 250 mg in 10 mL. Importantly, formulations sold under the REM Blend name can vary, so the actual composition should always be verified from the product specification.

How It Works

The formulation combines different sleep-related pathways. DSIP and Pinealon are research peptides, while melatonin participates directly in circadian signaling and GABA is the brain's primary inhibitory neurotransmitter.

POTENTIAL BENEFITS

1. Sleep Research

DSIP has historically been investigated for its relationship with sleep architecture and delta-wave activity. The peptide provides the primary sleep-focused research component of the blend.

2. Circadian Research

Melatonin is an established regulator of circadian timing and sleep-wake signaling. Its inclusion makes the formulation relevant to research examining biological-clock regulation.

3. Neuroendocrine Research

Pinealon has been investigated in cellular and animal research involving brain function, oxidative stress, and age-associated biological changes. Its presence broadens the blend into neuroendocrine and cellular-aging research.

4. GABAergic Research

GABA is the principal inhibitory neurotransmitter in the central nervous system. Research involving GABA-related signaling provides an additional pathway for investigating neuronal relaxation and sleep-related physiology.

Dosage

There is no standardized clinical dosage for REM Blend. Current listings describe different formulations and concentrations, and the combination itself has not been clinically validated as a single standardized preparation.

Side Effects

Potential effects depend on the individual ingredients and their concentrations. Melatonin and GABA can cause drowsiness, while the human safety evidence for DSIP/Pinealon combinations is limited. The complete blend has not undergone controlled clinical safety evaluation.

References

1. Sleep and circadian peptide-stack research, including REM Blend composition
2. DSIP research — PubMed
3. Pinealon research — PubMed
4. Melatonin and sleep/circadian research — PubMed
5. GABA and sleep research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

GHK-Cu + KPV Blend combines GHK-Cu (Copper Tripeptide-1) with KPV (Lys-Pro-Val) in a two-peptide research formulation. The individual peptides have distinct research profiles involving extracellular-matrix biology, skin remodeling, inflammation, and tissue repair.

Product Information

GHK-Cu is a copper-binding tripeptide extensively studied in skin and connective-tissue research. At the same time, KPV is the C-terminal tripeptide of alpha-MSH and has primarily been investigated in cellular and animal inflammation models. Current research-market formulations vary in composition, with reported combinations including 50 mg GHK-Cu + 10 mg KPV and 50 mg GHK-Cu + 20 mg KPV. There is no standardized formulation across suppliers.

How It Works

GHK-Cu is associated with extracellular matrix and collagen-related signaling, while KPV has been investigated for anti-inflammatory effects downstream of melanocortin pathways. The two peptides therefore represent complementary but distinct biological pathways.

POTENTIAL BENEFITS

1. Collagen Research

GHK-Cu has been studied extensively for its effects on collagen synthesis, fibroblast activity, and extracellular-matrix remodeling. These properties make it particularly relevant to skin and connective-tissue research.

2. Skin Remodeling Research

Research involving copper tripeptides has examined wound repair, skin structure, and tissue remodeling. GHK-Cu therefore provides the primary skin-focused component of this blend.

3. Inflammation Research

KPV has been investigated in experimental models of intestinal and cellular inflammation. Research has examined pathways involving inflammatory cytokines and NF-κB-related signaling.

4. Tissue-Repair Research

The individual components have been studied in different tissue-repair models, giving the combination a broader research profile spanning extracellular-matrix biology and inflammatory regulation.

Dosage

There is no established clinical dosage for the GHK-Cu + KPV combination. Current research-market formulations vary in their component ratios, and no controlled human study has established a validated dose for the premixed combination.

Side Effects

The safety profile of the complete combination has not been established in controlled human trials. GHK-Cu has the stronger human/topical research base, while KPV remains predominantly preclinical, so evidence for one component should not be interpreted as evidence for the complete blend.

References

1. GHK-Cu + KPV Blend — formulation and research overview
2. GHK-Cu + KPV Blend — ingredients and ratios
3. GHK-Cu connective-tissue research — PubMed
4. GHK-Cu and skin/wound-healing research — PubMed
5. KPV inflammatory-pathway research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Survodutide is a once-weekly dual glucagon and GLP-1 receptor agonist being investigated for obesity, metabolic disease, and metabolic dysfunction-associated steatohepatitis (MASH). Clinical trials have reported substantial body-weight reductions alongside metabolic and liver-related improvements.

Product Information

Survodutide activates both GLP-1 and glucagon receptors. Phase 2 research has evaluated it in adults with obesity and in people with MASH and liver fibrosis, with studies examining body weight, liver fat, fibrosis, glucose regulation, and other metabolic markers.

How It Works

GLP-1 receptor activation influences appetite and glucose regulation, while glucagon receptor activation affects energy metabolism and lipid handling. Survodutide combines these two signals into a single dual-action molecule.

Potential Benefits

1. Weight-Management Research

Phase 2 obesity research has demonstrated dose-dependent reductions in body weight with once-weekly survodutide. The strongest studied doses produced substantial average weight reductions over the treatment period.

2. Appetite Regulation

The GLP-1 component can reduce appetite and influence food intake, supporting the investigation of survodutide as a weight-management therapy.

3. Metabolic Support

Survodutide has been studied for effects on glucose-related and other metabolic biomarkers. Research has reported improvements in several measures related to metabolic function.

4. Liver Health Research

Survodutide has also been investigated in people with MASH and liver fibrosis. Phase 2 research has examined histological improvement, liver fat reduction, and changes in fibrosis.

Dosage

In a phase 2 obesity trial, survodutide was studied at once-weekly doses of 0.6, 2.4, 3.6, and 4.8 mg, using a dose-escalation and maintenance design over 46 weeks. These were research doses and should not be treated as individualized dosing instructions.

Side Effects

Gastrointestinal adverse effects are the most frequently reported issues in clinical research, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In the phase 2 obesity trial, gastrointestinal events were more common with survodutide than placebo.

References

1. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology. 2024;12(3):162-173. PMID: 38330987. PubMed
2. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 2024. PMID: 38847460. PubMed

BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.